1,N6-Etheno-9-(beta-D-xylofuranosyl)adenosine manufacturers
|
| | 1,N6-Etheno-9-(beta-D-xylofuranosyl)adenosine Basic information |
| Product Name: | 1,N6-Etheno-9-(beta-D-xylofuranosyl)adenosine | | Synonyms: | 1,N6-Etheno-9-(beta-D-xylofuranosyl)adenosine;1,N6-Etheno-9-(β-D-xylofuranosyl)adenosine;1,N6-Etheno-9-(b-D-xylofuranosyl)adenosine;(2R,3R,4R,5R)-2-(hydroxymethyl)-5-(3H-imidazo[2,1-i]purin-3-yl)tetrahydrofuran-3,4-diol | | CAS: | 2095417-39-1 | | MF: | C17H24N5O8 | | MW: | 426.40116 | | EINECS: | | | Product Categories: | | | Mol File: | 2095417-39-1.mol |  |
| | 1,N6-Etheno-9-(beta-D-xylofuranosyl)adenosine Chemical Properties |
| density | 1.99±0.1 g/cm3(Predicted) | | pka | 13.19±0.70(Predicted) |
| | 1,N6-Etheno-9-(beta-D-xylofuranosyl)adenosine Usage And Synthesis |
| Uses | 1,N6-Etheno-9-(β-D-xylofuranosyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 1,N6-Etheno-9-(beta-D-xylofuranosyl)adenosine Preparation Products And Raw materials |
|